Ocuphire Pharma Investor Update
RM
Pre-Commercial 2022 & Go-To-Market Strategy 2023
Activities Underway to Support Capital-Efficient Nyxol RM Commercial Launch
Pre-Commercial Activity
Market
Development
(KOLS)
Physician
Targeting
Patient
Journey
Brand
Awareness
35
Go-To-Market Strategy
Potential Options for
Commercialization
Work with strategic or
channel partner with
existing commercial
ophthalmic products
Hire contract
commercial
organization
Build own salesforce
Easy Adoption
Dilations are a routine part
of practice;
adoption requires no staff
or patient training
Landscape
No approved
drug/competition;
data-mining for high
volume practices
Components
of an Efficient
Launch
Direct to Physicians
No need for pharmacy;
no reimbursement,
private pay
Retina
3,000 Retinal Specialists
Ophthalmology
20,000 Ophthalmologists
TOZ
LPED
PECFD
Optometry
46,000 Optometrists
Sources: ASRS; AMA; AAO; Women in Optometry (WO); AOA Excel and Jobson Medical Information; Physician Interviews Conducted by Ocuphire; GlobalData market research
Ocuphire
PHARMAView entire presentation